skip to main content
Idioma:
Tipo de recurso Mostra resultados com: Mostra resultados com: Índice

Antimelanoma differentiation‐associated protein 5 antibody level is a novel tool for monitoring disease activity in rapidly progressive interstitial lung disease with dermatomyositis

Matsushita, T. ; Mizumaki, K. ; Kano, M. ; Yagi, N. ; Tennichi, M. ; Takeuchi, A. ; Okamoto, Y. ; Hamaguchi, Y. ; Murakami, A. ; Hasegawa, M. ; Kuwana, M. ; Fujimoto, M. ; Takehara, K.

British journal of dermatology (1951), 2017-02, Vol.176 (2), p.395-402 [Periódico revisado por pares]

England: Oxford University Press

Texto completo disponível

Citações Citado por
  • Título:
    Antimelanoma differentiation‐associated protein 5 antibody level is a novel tool for monitoring disease activity in rapidly progressive interstitial lung disease with dermatomyositis
  • Autor: Matsushita, T. ; Mizumaki, K. ; Kano, M. ; Yagi, N. ; Tennichi, M. ; Takeuchi, A. ; Okamoto, Y. ; Hamaguchi, Y. ; Murakami, A. ; Hasegawa, M. ; Kuwana, M. ; Fujimoto, M. ; Takehara, K.
  • Assuntos: Adrenal Cortex Hormones - therapeutic use ; Antibodies ; Autoantibodies ; Autoantibodies - metabolism ; Corticosteroids ; Cyclophosphamide ; Cyclophosphamide - therapeutic use ; Dermatologic Agents - therapeutic use ; Dermatomyositis ; Dermatomyositis - drug therapy ; Dermatomyositis - immunology ; Drug Therapy, Combination ; Female ; Humans ; Immunosuppressive agents ; Immunosuppressive Agents - therapeutic use ; Interferon-Induced Helicase, IFIH1 - immunology ; Intravenous administration ; Lung diseases ; Lung Diseases, Interstitial - drug therapy ; Lung Diseases, Interstitial - immunology ; Male ; Middle Aged ; Myositis ; Proteins ; Recurrence ; Remission ; Tacrolimus ; Treatment Outcome ; Vaccines
  • É parte de: British journal of dermatology (1951), 2017-02, Vol.176 (2), p.395-402
  • Notas: Conflicts of interest
    M.K. holds a patent on the anti‐MDA5 antibody measurement system. A.M. is an employee of Medical and Biological Laboratories. The remaining authors state that they have no conflicts of interest.
    ObjectType-Article-1
    SourceType-Scholarly Journals-1
    ObjectType-Feature-2
    content type line 23
  • Descrição: Summary Background Antimelanoma differentiation‐associated protein (anti‐MDA)5 antibodies are associated with rapidly progressive interstitial lung disease (RP‐ILD) in patients with clinically amyopathic dermatomyositis (CADM) or dermatomyositis (DM). Objectives We aimed to evaluate the relevance of monitoring anti‐MDA5 antibody levels for the management of RP‐ILD in patients with CADM or DM. Methods Twelve patients with CADM (n = 10) or DM (n = 2) accompanied by RP‐ILD were included. Baseline characteristics and outcomes were recorded. Serial measurements of anti‐MDA5 antibody levels were measured. All patients were treated with corticosteroids, tacrolimus and intravenous cyclophosphamide. Results All patients achieved RP‐ILD remission after combined immunosuppressive therapy for a mean of 6·8 months, with significant decreases noted in the mean anti‐MDA5 antibody levels at remission. Six (50%) patients became anti‐MDA5 antibody negative after therapy. After a mean follow‐up of 31 months, RP‐ILD relapse was observed in four (33%) patients in both the anti‐MDA5 antibody sustained positive group and the negative conversion group. However, relapsed patients in the sustained positive group relapsed earlier than those in the negative conversion group. Thus, a decrease in anti‐MDA5 antibody levels during remission was associated with longer remission. Relapses were associated with a reincrease of anti‐MDA5 antibody levels in four of four (100%) patients. In contrast, none of the patients without reincrease in anti‐MDA5 antibody exhibited symptoms of relapse during follow‐up. Therefore, reincrease in anti‐MDA5 antibody levels was associated with relapse. Conclusions The anti‐MDA5 antibody level is a novel parameter for monitoring and a good predictor of RP‐ILD relapse in patients with CADM or DM. What's already known about this topic? Myositis‐specific autoantibodies are strongly associated with distinct clinical phenotypes; thus, they can be used to classify patients into groups with more homogeneous clinical features. Antimelanoma differentiation‐associated protein (anti‐MDA)5 antibodies are specifically expressed in patients with clinically amyopathic dermatomyositis (CADM) or dermatomyositis (DM), and are associated with rapidly progressive interstitial lung disease (RP‐ILD). What does this study add? Anti‐MDA5 antibody levels correlate with disease activity. Relapse is associated with a reincrease in anti‐MDA5 antibody levels. What is the translational message? Anti‐MDA5 antibody levels are a novel parameter for monitoring and a good predictor of RP‐ILD relapse in patients with CADM/DM. Linked Comment: Jordan and Ghoreschi. Br J Dermatol 2017; 176:294–295. Respond to this article
  • Editor: England: Oxford University Press
  • Idioma: Inglês
Links
Voltar para lista de resultados

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.